Published in Pharm Res on March 01, 2004
RXLR-mediated entry of Phytophthora sojae effector Avr1b into soybean cells does not require pathogen-encoded machinery. Plant Cell (2008) 2.72
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
A polymeric domain that promotes cellular internalization. J Am Chem Soc (2008) 1.49
Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J (2007) 1.44
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem (2009) 1.34
The congenital disorders of glycosylation: a multifaceted group of syndromes. NeuroRx (2006) 1.33
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints. ACS Chem Biol (2012) 1.26
Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules (2009) 1.24
Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J (2007) 1.20
Synthetic and natural polycationic polymer nanoparticles interact selectively with fluid-phase domains of DMPC lipid bilayers. Langmuir (2005) 1.13
Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter conjugates in transgenic reporter mice. Proc Natl Acad Sci U S A (2007) 1.12
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm (2009) 1.12
Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev (2010) 1.02
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun (2012) 0.96
Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm (2009) 0.96
Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J Virol (2006) 0.95
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. J Invest Dermatol (2008) 0.94
Engineering persister-specific antibiotics with synergistic antimicrobial functions. ACS Nano (2014) 0.93
Guanidine-Containing Methacrylamide (Co)polymers via aRAFT: Toward a Cell Penetrating Peptide Mimic(). ACS Macro Lett (2011) 0.92
Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients. Biochim Biophys Acta (2009) 0.92
Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J Biomed Mater Res A (2013) 0.90
"Soft" calcium crosslinks enable highly efficient gene transfection using TAT peptide. Pharm Res (2009) 0.88
Nona-arginine facilitates delivery of quantum dots into cells via multiple pathways. J Biomed Biotechnol (2010) 0.88
Real-time transmembrane translocation of penetratin driven by light-generated proton pumping. Biophys J (2006) 0.88
Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel) (2012) 0.87
Rational design of a biomimetic cell penetrating peptide library. ACS Nano (2013) 0.84
Identification of a novel cell-penetrating peptide from human phosphatidate phosphatase LPIN3. Mol Cells (2012) 0.83
Development of protein mimics for intracellular delivery. Biopolymers (2015) 0.81
Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. J Control Release (2013) 0.81
Chimeric RNase H-competent oligonucleotides directed to the HIV-1 Rev response element. Bioorg Med Chem (2007) 0.80
Multilayered films fabricated from an oligoarginine-conjugated protein promote efficient surface-mediated protein transduction. Biomacromolecules (2007) 0.80
Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges. Biomed Res Int (2015) 0.80
Membrane surface-associated helices promote lipid interactions and cellular uptake of human calcitonin-derived cell penetrating peptides. Biophys J (2005) 0.80
Neuroprotective effect of TAT PTD-Ngb fusion protein on primary cortical neurons against hypoxia-induced apoptosis. Neurol Sci (2013) 0.80
Small-molecule regulators that mimic transcription factors. Biochim Biophys Acta (2010) 0.80
Peptoid transporters: effects of cationic, amphipathic structure on their cellular uptake. Mol Biosyst (2012) 0.80
Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy. Virol J (2007) 0.79
Optimal Hydrophobicity in Ring-Opening Metathesis Polymerization-Based Protein Mimics Required for siRNA Internalization. Biomacromolecules (2016) 0.79
Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens. Mol Pharm (2014) 0.78
TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability. Proc Natl Acad Sci U S A (2015) 0.78
Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng (2015) 0.78
The Role of Cell-Penetrating Peptide and Transferrin on Enhanced Delivery of Drug to Brain. Int J Mol Sci (2016) 0.78
Fibrinogen-derived fibrinostatin inhibits tumor growth through anti-angiogenesis. Cancer Sci (2015) 0.78
Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus. Oncotarget (2015) 0.77
The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders. Pharmaceuticals (Basel) (2013) 0.76
AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray. Mol Cancer Ther (2015) 0.76
CPP2-p16MIS treatment-induced colon carcinoma cell death in vitro and prolonged lifespan of tumor-bearing mice. BMC Cancer (2016) 0.76
PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study. Pharm Res (2015) 0.76
A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm Sin B (2014) 0.76
Cyclodextrin-PEI-Tat Polymer as a Vector for Plasmid DNA Delivery to Placenta Mesenchymal Stem Cells. Bionanoscience (2011) 0.76
Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulations. Arch Pharm Res (2016) 0.75
Structural Elucidation of the Cell-Penetrating Penetratin Peptide in Model Membranes at the Atomic Level: Probing Hydrophobic Interactions in the Blood-Brain Barrier. Biochemistry (2016) 0.75
Membrane transducing activity of recombinant Hoxc8 protein and its possible application as a gene delivery vector. Exp Mol Med (2008) 0.75
Endotoxin deactivation by transient acidification. Cell Transplant (2010) 0.75
Fluorogenic Substrates for In Situ Monitoring of Caspase-3 Activity in Live Cells. PLoS One (2016) 0.75
Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med (2004) 6.48
CDK inhibitors: cell cycle regulators and beyond. Dev Cell (2008) 5.07
Protein transduction technology. Curr Opin Biotechnol (2002) 2.90
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood (2008) 2.85
Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release (2005) 2.74
TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med (2007) 2.60
Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev (2004) 2.47
Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol (2011) 1.85
Novel p27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol (2003) 1.85
Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev (2007) 1.71
Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev (2004) 1.65
Regulation of late G1/S phase transition and APC Cdh1 by reactive oxygen species. Mol Cell Biol (2006) 1.65
Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol (2009) 1.59
Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev (2002) 1.58
Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell (2013) 1.47
Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol (2004) 1.38
Relocalized p27Kip1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res (2007) 1.35
Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev (2007) 1.34
Revised role of glycosaminoglycans in TAT protein transduction domain-mediated cellular transduction. J Biol Chem (2009) 1.31
Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization. Blood (2007) 1.28
Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci (2003) 1.13
Medicine. Targeting apoptotic pathways in cancer cells. Science (2004) 1.13
Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv (2006) 1.12
C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A (2010) 1.09
Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res (2008) 1.09
siRNA delivery using peptide transduction domains. Trends Pharmacol Sci (2009) 1.07
Pathologic prion protein infects cells by lipid-raft dependent macropinocytosis. PLoS One (2008) 1.07
The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci (2006) 1.06
A systems biology dynamical model of mammalian G1 cell cycle progression. Mol Syst Biol (2007) 1.05
Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv (2005) 1.04
Protein transduction technology offers novel therapeutic approach for brain ischemia. Trends Pharmacol Sci (2003) 0.97
Whi5 regulation by site specific CDK-phosphorylation in Saccharomyces cerevisiae. PLoS One (2009) 0.97
Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proc Natl Acad Sci U S A (2003) 0.95
Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J Immunol (2003) 0.94
PTD/CPP peptide-mediated delivery of siRNAs. Curr Pharm Des (2013) 0.93
Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther (2009) 0.93
The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla. Discov Med (2009) 0.92
c-Rel regulation of the cell cycle in primary mouse B lymphocytes. Int Immunol (2002) 0.91
Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. J Control Release (2003) 0.91
Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Res (2005) 0.90
Protein transduction: generation of full-length transducible proteins using the TAT system. Curr Protoc Cell Biol (2003) 0.90
Excision of selectable genes from transgenic goat cells by a protein transducible TAT-Cre recombinase. Gene (2008) 0.89
A novel role for survivin in erythroblast enucleation. Haematologica (2012) 0.89
The anonymous American Idol manuscript reviewer. Cell (2006) 0.85
Do cell-penetrating peptides actually "penetrate" cellular membranes? Mol Ther (2012) 0.85
Efficient siRNA delivery by novel PTD-DRBD fusion proteins. Cell Cycle (2010) 0.84
Synthesis of a pH-sensitive nitrilotriacetic linker to peptide transduction domains to enable intracellular delivery of histidine imidazole ring-containing macromolecules. J Am Chem Soc (2010) 0.82
PTD-DRBD siRNA delivery. Methods Mol Biol (2011) 0.79
Cellular activity of siRNA oligonucleotides containing synthetic isomorphic nucleoside surrogates. Chem Commun (Camb) (2015) 0.79
Another twist in the transforming growth factor beta-induced cell-cycle arrest chronicle. Proc Natl Acad Sci U S A (2003) 0.79
DNA delivery into mammalian cells using bacteriophage λ displaying the TAT transduction domain. Cold Spring Harb Protoc (2013) 0.78
14. From bench to bedside: cationic TAT peptide transduction domain enters cells by macropinocytosis (2005): Original research article: Cationic TAT peptide transduction domain enters cells by macropinocytosis, 2005. J Control Release (2014) 0.75